Test Price
600 AED✅ Home Collection Available
Immunohistochemistry Thyroid Carcinoma Panel in Dubai | Accurate Thyroid Cancer Subtyping | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
Your precision partner for thyroid cancer subtyping: 99.9% diagnostic sensitivity via ISO-accredited immunohistochemistry on FFPE tissue. Secure Medical Courier Solid Tissue Specimen Retrieval ensures safe transport of archival blocks. Post-test telephonic clinical guidance provides clarity and confidence in every result. Direct billing verification via WhatsApp at +971 54 548 8731.
Base price: 600 AED | Turnaround: 5–7 working days | DHA licensed facility 1143
Test Overview & Methodology
The Immunohistochemistry Thyroid Carcinoma Panel is an advanced tissue-based test that identifies specific protein markers—including TTF-1, Thyroglobulin, Calcitonin, and BRAF V600E—to accurately classify thyroid carcinomas (papillary, follicular, medullary, anaplastic) directly from formalin-fixed paraffin-embedded (FFPE) biopsy samples. This panel provides essential prognostic and therapeutic guidance for personalized oncology care.
| Feature | Our Test (ISO 9001:2015 Accredited) | Standard Histopathology (H&E Only) |
|---|---|---|
| Precision | Multiplex IHC with automated quantitative scoring; 99.9% diagnostic sensitivity | Morphological assessment; subjective grading; may miss molecular subtypes |
| Method | DAB chromogen detection using validated monoclonal antibodies on FFPE tissue | Hematoxylin & Eosin staining; no protein-level differentiation |
| Speed | Report in 5 working days (complex cases 7 days) | Typically 7–10 working days; often requires additional IHC referral |
Physician Insight & Safety Protocols
“Immunohistochemistry provides vital prognostic and therapeutic markers; however, it must always be interpreted in conjunction with full clinical and radiological findings. No single test replaces comprehensive oncology evaluation. Please consult your treating oncologist before any treatment decisions.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA ID: 61713011
Advisory – Medication and Treatment
Never discontinue prescribed medication or alter treatment without explicit guidance from your treating physician. Thyroid hormone suppression or anti-cancer therapy must be managed exclusively by a licensed specialist.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Tissue sample not fixed in 10% neutral buffered formalin; insufficient viable tumor content (less than 10%); missing histopathology report or biopsy site documentation.
- Exclusion: Frozen or decalcified specimens without prior validation; specimens with prolonged ischemia (over 30 minutes).
- Emergency Red Flags: Rapidly enlarging neck mass, stridor, hoarseness, dysphagia, or signs of superior vena cava syndrome. Seek immediate emergency medical attention if these develop.
Patient FAQ & Clinical Guidance
1. What is the Immunohistochemistry Thyroid Carcinoma Panel?
A tissue-based test that uses antibody staining to detect specific proteins on thyroid cancer cells, aiding precise subtype diagnosis and treatment planning. This panel examines markers such as TTF-1, Thyroglobulin, Calcitonin, and BRAF V600E immunohistochemically on FFPE tissue blocks. Results are integrated with histopathology to distinguish papillary, follicular, medullary, and anaplastic carcinomas, guiding targeted therapy decisions.
2. How is the sample collected and prepared for this test?
An existing FFPE tissue block or unstained slides from a previous biopsy or surgical excision must be provided. The specimen is retrieved via Secure Medical Courier Solid Tissue Specimen Retrieval – no blood draw or home phlebotomy is required. Please include the original histopathology report, biopsy site details, and complete clinical history for accurate interpretation.
3. Does this replace genetic testing for thyroid cancer?
No, immunohistochemistry detects protein expression, while genetic testing identifies DNA mutations; both are complementary for comprehensive thyroid cancer profiling. This IHC panel reveals functional protein status (e.g., BRAF V600E mutant protein) and can guide targeted therapy. However, definitive genomic analysis may still be recommended for hereditary syndromes or to assess somatic mutations not covered by IHC. Always follow your oncologist’s advice on integrative testing.
UAE Regulatory & Data Privacy Adherence
Our laboratory strictly complies with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is handled with the highest confidentiality and security standards. Clinical testing and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry Thyroid Carcinoma Panel |
| Price (AED) | 600 AED |
| Turnaround Time | 5 working days (complex cases up to 7 working days) |
| Sample Type / Matrix | Formalin-fixed paraffin-embedded (FFPE) tissue block or unstained slides |
| Methodology Used | Immunohistochemistry (IHC) using DAB chromogen detection with validated monoclonal antibodies |
| ICD-10-CM Code | C73.9 (Malignant neoplasm of thyroid gland, unspecified) |
| LOINC Code | 104283-3 (Thyroid carcinoma panel - Microscopy observation panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians